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Antimicrobial	drug	treatment	of	travelers’	diarrhea	is	known	
to	increase	the	risk	for	colonization	with	extended-spectrum	
b-lactamase-producing	 Enterobacteriaceae.	 Among	 288	
travelers	with	travelers’	diarrhea,	the	colonization	rate	with-
out	medications	was	21%.	For	 treatment	with	 loperamide	
only,	the	rate	was	20%;	with	antimicrobial	drugs	alone,	40%;	
and	with	loperamide	and	antimicrobial	drugs,	71%.	
Resistance to antimicrobial drugs (AMDs) is predis-posed in areas with poor hygiene and weak or non-
existent antimicrobial policy. Travelers visiting these 
areas presumably have a central role as transporters of 
multidrug-resistant intestinal bacteria across the globe (1), 
because a significant proportion of travelers (20%–70%) 
to high-prevalence areas become colonized with extend-
ed-spectrum β-lactamase-producing Enterobacteriaceae 
(ESBL-E) (2–7). Clinical infections do not develop in most 
travelers (6), and colonization is transient, waning within 
months (7). However, as evidenced by intrahousehold 
transmission from colonized patients after hospitalization, 
the bacteria may spread to household members (8,9) and 
eventually to local healthcare settings in the home coun-
tries of the travelers.
Several factors have been identified to increase the 
risk for ESBL-E colonization: travel destination (2–7), 
travelers’ diarrhea (TD) (2,6,7), use of AMDs (5–7), and 
age (2,6). In a recent study, we found that ESBL-E was 
contracted by 11% of travelers who did not have TD and 
did not take AMDs (TD–AMD–), 21% of those with TD 
who did not take AMDs (TD+AMD–), and 37% of those 
with TD who took AMDs (TD+AMD+) (6). Our conclu-
sion that mild or moderate diarrhea should not be treated 
with AMDs raised questions about safe alternatives (10). 
In our previous study, probiotics appeared not to affect 
colonization (6). We found no studies that assessed pos-
sible risks posed by non-AMD antidiarrheal medications 
for treating TD, such as loperamide.
Loperamide, a drug with both antisecretory and anti-
motility effects (11), is widely used by travelers (12). Al-
though mostly used alone, loperamide is sometimes used 
with AMDs; the combination stops symptoms faster than 
AMDs alone during the first 2 days of TD. After that, the 
combination no longer appears advantageous, probably be-
cause symptoms resolve naturally (11). Using loperamide 
with AMDs is presented as a safe option in general guide-
lines published by the US Centers for Disease Control and 
Prevention (13). However, the effects of co-administration 
on the risk for ESBL-E acquisition have not been addressed.
Some researchers have posed the question as to wheth-
er the antimotility effect of loperamide, involving pro-
longed passage through the gastrointestinal tract, would, in 
fact, increase the risk for colonization (data not shown). 
Such speculations prompted us to revisit our recent data (6) 
to compare loperamide, AMDs, and their combination in 
the treatment of TD with regard to the risk for contracting 
travel-acquired ESBL-E.
The Study
We reviewed our recent data on ESBL-E acquisition 
among 430 travelers from Finland (6), selecting those with 
TD for separate analysis (Figure). All the volunteers pro-
vided fecal samples and completed questionnaires before 
and after travel. Symptoms of TD and use of medications, 
such as loperamide and AMDs, were included in the post-
travel questionnaires. The countries visited were grouped 
as described (Table 1; 6); processing of fecal specimens 
and identification of ESBL-E were detailed in our previous 
study (6). TD was defined by the World Health Organiza-
tion criteria: passing >3 loose/liquid stools per 24 hours, or 
more frequently than normal (14).
Study participants were divided into 4 groups by treat-
ment of TD: those taking no loperamide or AMDs (LO–
AMD–); only loperamide (LO+AMD–); only AMDs (LO–
AMD+); or loperamide plus AMDs (LO+AMD+). Those 
having taken AMDs for non-TD indications were catego-
rized in groups with those with TD who took AMDs.
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DISPATCHES
We used a multivariable binary logistic regression mod-
el to test our main hypotheses. Loperamide, AMDs, and their 
interaction (effect modification) were included in the model, 
along with risk factors that showed a p value <0.2 in univari-
ate analysis in our previous study (6): sex, travel destination, 
use of AMDs, meals with residents of the location, contact 
with local healthcare, sites of meals, accommodations, dura-
tion of travel, age, and use of alcohol. Variables were elimi-
nated to the final model by using backward selection of fac-
tors by Akaike Information Criteria, except for loperamide 
and the use of AMDs and their interaction, which were 
forced to the final model. Missing values were taken into ac-
count by multiple imputations, to reduce possible biases and 
efficiency loss, assuming that data were missing at random. 
We analyzed statistics using SPSS statistical software ver-
sion 21 (IBM Corporation, Armonk, NY, USA).
Of all travelers in the previous study (6), a total of 
288 of 430 (67%) who reported TD constituted the final 
study group (Table 1). ESBL-E was contracted by 26% 
of the subjects: 21% in the LO–AMD– group; 20% in the 
LO+AMD– group (adjusted odds ratio [aOR] 0.8, 95% CI 
0.4–1.7); 40% in the AMD+LO– group (aOR 2.9, 95% CI 
1.2–7.4); and 71% in the LO+AMD+ group (aOR 7.4, 95% 
CI 1.7–32.6) (Table 2). aOR for the interaction term of lop-
eramide and AMDs was 3.1 (95% CI 0.6–16.6). Travel des-
tination remained an independent risk factor, and sharing 
meals with locals appeared protective (Table 2). 
Studies showing AMD treatment of patients with TD 
to be an independent risk factor for contracting ESBL-
E (5–7) have evoked the question of less harmful treat-
ments. The recommendation to restrict AMDs to severe 
cases (5,6,15) seems reasonable, as TD generally remains 
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Figure.	Study	protocol	for	
investigating	risk	for	contracting	
ESBL-producing	Enterobacteriaceae 
among	travelers	from	Finland	with	
TD.	LO–AMD–,	not	treated	with	
medication;	LO+AMD–,	treated	with	
LO	alone;	LO–AMD+,	treated	with	
AMDs	alone;	LO+AMD+,	treated	
with	a	combination	of	both	drugs.	
AMD,	antimicrobial	drugs;	ESBL,	
extended-spectrum	β-lactamase;	
LO,	loperamide;	TD,	travelers’	
diarrhea.
 
Table 1. Characteristics	of	and	co-administered	treatments	for	288	travelers	with	travelers’ diarrhea* 
Characteristics Total	no.	(%) 
LO–AMD– 
no.	(%) 
LO+AMD– 
no.	(%) 
LO–AMD+  
no.	(%) 
LO+AMD+	
no.	(%) 
Total 288 139	(48) 90	(31) 45	(16) 14	(5) 
Sex 
 F 180	(62) 86	(62) 54	(60) 32	(71) 8	(57) 
 M 108	(38) 53	(38) 36	(40) 13	(29) 6	(43) 
Age,	y,	median	(IQR) 34	(25) 34	(26) 34	(23) 35	(24) 31	(38) 
Geographic	region 
 South	Asia 46	(16) 19 (14) 17	(19) 5	(11) 5	(36) 
 Southeast	Asia 78	(27) 41	(29) 24	(27) 10	(22) 3	(21) 
 East Asia 4	(1) 1	(1) 1	(1) 2	(4) 0	(0) 
 Sub-Saharan	Africa 130	(45) 62	(45) 39	(43) 23	(51) 6	(43) 
 North	Africa	and	Middle	East 5	(2) 3	(2) 1	(1) 1	(2) 0	(0) 
 South	and	Central	America	and	the	Caribbean 23	(8) 12	(9) 7	(8) 4	(9) 0	(0) 
 Europe	and	North	America 2	(1) 1	(1) 1	(1) 0	(0) 0	(0) 
*LO,	loperamide;	AMD,	antimicrobial	drugs. 
 
Loperamide	and	Antimicrobial	Drugs
mild or moderate and resolves spontaneously (12,15). 
If symptoms require medical treatment, loperamide ap-
pears to be a sensible alternative for travelers who have 
no fever or bloody stools. However, because of its an-
timotility effect, its safety against contracting resistant 
intestinal bacteria has been questioned. Among studies 
that explored risk factors for ESBL carriage, we found 
none that showed data on the use of loperamide alone or 
in combination with AMDs.
Consistent with our previous analysis (6), we found 
AMD treatment of TD was an independent risk factor for 
colonization with ESBL-E; the rate increased from 21% 
(LO–AB–) to 40% (LO–AB+) (aOR 2.9, 95% CI 1.2–7.4). 
When used alone, loperamide did not add to the risk (20% 
colonized in the LO+AB– group).
In the group taking both loperamide and AMDs, the 
colonization rate was strikingly high, increasing from 21% 
(LO–AB–) to 71% (LO+AB+). The rate also appeared to 
exceed the risk for using AMDs alone (40%), yet the in-
teraction term of loperamide and AMDs did not reach sta-
tistical significance (aOR 3.1, 95% CI 0.6–16.6), and the 
small subject number resulted in wide CIs. Theoretically, 
an additional increase in the risk seen in the combination 
group could be brought about by loperamide: because of 
its antimotility effect, contact time of the AMD to the gut 
lumen is increased, and the selection pressure posed by 
the AMD may be prolonged, thus intensifying its unfavor-
able effects. 
Our study design was limited by not including a ran-
domized allocation of therapy and the varied use of lop-
eramide according to symptoms. However, no association 
was seen between the severity of symptoms and acquisition 
of ESBL-E (data not shown).
Studies are needed to compare the relative risk 
posed by various AMD classes. Exploration of the 
influence of nonantimicrobial antidiarrheal agents with 
only antisecretory effect, such as racecadotril, as mono-
therapy and in combination with AMDs would also 
be beneficial. 
Conclusions
Our results show that loperamide alone offers a safe alter-
native to AMDs for TD treatment, because it does not add 
to the risk for acquiring drug-resistant intestinal bacteria. 
In contrast, combining loperamide with AMDs predispos-
es to ESBL-E colonization and may add to the substantial 
risk posed by AMDs alone. Our data dispute the safety of 
this combination.
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Table 2. Multivariable	analysis	of	acquisition	of	extended-spectrum	-lactamase-producing	Enterobacteriaceae by	288	travelers	on	the	
basis	of	administration	of	treatments	for	travelers’ diarrhea*† 
Characteristics 
Total,	no.	
(%) 
ESBL	
neg,	no.	
(%) 
ESBL	pos,	
no.	(%) 
Univariate	analysis 
 
Multivariable	analysis	with	
imputation 
p	value OR	(95%	CI) p	value aOR	(95%	CI) 
Total 288	(100) 213	(74) 75	(26) NA NA  NA NA 
Study	groups         
 LO–AMD– 139	(48) 110	(79) 29	(21) NA 1.0  NA 1.0 
 LO+AMD– 90	(31) 72	(80) 18	(20) 0.874 0.9	(0.5–1.8)  0.583 0.8	(0.4–1.7) 
 LO–AMD+‡ 45	(16) 27	(60) 18	(40) 0.012 2.5	(1.2–5.2)  0.022 2.9	(1.2–7.4) 
 LO+AMD+ 14	(5) 4	(29) 10	(71) <0.001 9.5	(2.8–32.4)  0.008 7.4	(1.7–32.6)§ 
Travel	destination         
 South	Asia 46	(16) 21	(46) 25	(54) NA 1.0  NA 1.0 
 Southeast	Asia 78	(27) 48	(62) 30	(38) 0.087 0.5	(0.3–1.1)  0.186 0.6	(0.3–1.3) 
 East Asia 4	(1) 2	(50) 2	(50) 0.867 0.8	(0.1–6.5)  0.989 1.0	(0.1–12.3) 
 Sub-Saharan	Africa 130	(45) 114	(88) 16	(12) <0.001 0.1	(0.1–0.3)  <0.001 0.1	(0.05–0.3) 
 North	Africa	and	Middle	East 5	(2) 3	(60) 2	(40) 0.546 0.6	(0.1–6.7)  0.536 0.5	(0.1–3.8) 
 South	and	Central	America	and	
the	Caribbean 
23	(8) 23	(100) 0 NA NA  NA NA 
 Europe	and	North	America 2	(1) 2	(100) 0 NA NA  NA NA 
Other	factors         
 Sharing	meals	with	locals¶ 52	(19) 46	(88) 6	(12) 0.01 0.3	(0.1–0.8)  0.017 0.3	(0.1–0.8) 
 Contact	with	local	healthcare 32	(11) 18	(56) 14	(44) <0.001 2.5	(1.2–5.3)  0.314 1.7	(0.6–4.7) 
*ESBL,	extended-spectrum β-lactamase;	OR,	odds	ratio;	aOR,	adjusted	odds	ratio;	LO,	loperamide;	AMD,	antimicrobial	drugs;	LO–AMD–,not	treated	with	
medication;	LO+AMD–,	treated	with	LO	alone;	LO–AMD+,	treated	with	AMDs	alone; LO+AMD+,	treated	with	a	combination	of	both	drugs;	NA,	not	
applicable;	pos,	positive;	neg,	negative. 
†Values represent proportions with a given risk factor, aOR and p values in univariate and multivariable analysis. By using backward	selection	of	factors	
by	Akaike	Information	Criteria,	the	following	factors	were	eliminated	of	the	variables	in	the	final	model:	age,	duration	of	travel,	sex,	alcohol,	site	of	meals,	
and	type	of	accommodation. 
‡Includes 7 travelers having taken antimicrobial drugs for indications	other	than	TD. 
§aOR	for	interaction	term	of	loperamide	and	AMDs	is	3.1	(95%	CI	0.6–16.6). 
¶Information	missing	for	18	travelers. 
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